TAFI deficient human plasma

Description
Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Plasma is manufactured from pooled normal human plasma depleted of TAFI using antibodies directed to TAFI. Only the highest quality citrated plasma is used as starting material.

Application
For research assays of TAFI antigen and functionality as a negative control and for dilution of standards and test samples.
 
Warning
The plasma is prepared from screened normal citrated human plasma that have been tested and found negative for HIV and Hepatitis by FDA-approved methods.
As no known test method can provide complete assurance that products derived from human blood will not transmit HBsAg, HCV, HIV-1, HIV-2 or other blood-borne pathogens, this reagent should be handled as recommended for any potentially infectious human specimen.

Presentation
Set of 5 clear, screw-capped vials each containing 1 mL of lyophilized plasma. The plasma contains 50mM HEPES and stabilizers.

Reconstitution and Stability
One vial of lyophilized product is reconstituted by addition of 1 mL of distilled water, employing gentle agitation for 15 minutes, at room temperature. Stability after reconstitution is 4 hours at ambient (18° -25°C), or 30 days at -20 °C.

Storage
Prior to reconstitution, dried plasma should be stored at 2° - 8°C.

Category: Research use only

Type: Deficient Plasma

Product Availability: Worldwide

Manufacturer: ImmBioMed GmbH & Co KG, Germany

For more information please click .pdf icon below.